search
Back to results

Perceptual Decision Making Under Conditions of Visual Uncertainty

Primary Purpose

Parkinson's Disease, Dystonia, Ataxia

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Deep Brain Stimulation (DBS)
Sponsored by
University of California, Los Angeles
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Parkinson's Disease

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Group 1 - Age and Sex matched healthy controls:
  • Age 18-80 Years

Group 2 - Patients with Parkinson's Disease - No DBS:

  • "on meds" and "off meds" (tested in separate sessions) - total of 2 sessions
  • Age 45-80 Years
  • Unified PD rating scale (UPDRS)
  • Mini mental health Status (MMHS)

Group 3 - Patients with Parkinson's Disease already consented for DBS (STN):

  • Age 45-80 Years
  • Unified PD rating scale (UPDRS)
  • Mini mental health Status (MMHS)

Group 4 - Patients with Parkinson's Disease already consented for DBS (GPi):

  • Age 45-80 Years
  • Unified PD rating scale (UPDRS)
  • Mini mental health Status (MMHS)

Group 5 - Patients with Cervical Dystonia - No DBS

  • Age 30-80 years
  • Fahn-Marsden dystonia rating scale (FMDRS)
  • Mini mental health Status (MMHS)

Group 6 - Patients with Generalized Dystonia (Ach) - No DBS:

  • Age 30-80 years
  • Fahn-Marsden dystonia rating scale (FMDRS)
  • Mini mental health Status (MMHS)

Group 7 - Patients with Dystonia already consented for DBS (GPi):

  • Age 30-80 years
  • Fahn-Marsden dystonia rating scale (FMDRS)
  • Mini mental health Status (MMHS)

Group 8 - Patients Cerebellar Stroke

  • Age 30-80 Years
  • Routine neuro exam
  • Mini mental health Status (MMHS)

Group 9 - Patients Cerebellar Ataxia

  • Age 30-80 Years
  • Routine neuro exam
  • Mini mental health Status (MMHS)

Exclusion Criteria:

  • Visual impairment or ocular motility disorder Inability to sit for the 30 minute task plus 20-30 minute instruction time, setup, and wait time.

For Group 1 (Age Sex Matched Controls), there will additional exclusion criteria of other neurological disease and drug use

Sites / Locations

  • Neuroscience Research BuildingRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Deep Brain Stimulator

Arm Description

Some of our subjects that participate to the study have Deep Brain Stimulation implanted. They will perform the behavioral task twice, with the stimulation ON or OFF.

Outcomes

Primary Outcome Measures

Choice performance - % correct responses out of total number of trials
data from each subject will be assessed at the end of each session to monitor and measure outcome measures.

Secondary Outcome Measures

Reaction Time to make a choice - measured in milliseconds
data from each subject will be assessed at the end of each session to monitor and measure outcome measures.

Full Information

First Posted
April 23, 2013
Last Updated
December 17, 2015
Sponsor
University of California, Los Angeles
Collaborators
The Dana Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT01845883
Brief Title
Perceptual Decision Making Under Conditions of Visual Uncertainty
Official Title
Perceptual Decision Making Under Conditions of Visual Uncertainty
Study Type
Interventional

2. Study Status

Record Verification Date
December 2015
Overall Recruitment Status
Unknown status
Study Start Date
April 2013 (undefined)
Primary Completion Date
December 2015 (Anticipated)
Study Completion Date
December 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Los Angeles
Collaborators
The Dana Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In this proposal the investigators have three Specific Aims using human patient populations as model systems; 1) identify a role for the Basal Ganglia (BG) in perceptual decision making; 2) determine whether the Basal Ganglia contribute to decision making under conditions of visual uncertainty; 3) determine whether the cerebellum plays a role in perceptual decision-making under conditions of visual uncertainty. The investigators designed experiments using healthy humans and humans with diseases known to affect the Basal Ganglia and the cerebellum, Parkinson's Disease, dystonia and non-dystonic cerebellar damage. With this approach the investigators will test the following hypotheses: 1) Patients with Parkinson's Disease and dystonia will have more difficulty than healthy controls making perceptual decisions when faced with sensory uncertainty; when sensory information is certain, patients will show improved decision-making but will still be impaired relative to healthy humans. Hypothesis 2: If ambiguous sensory information is aided by prior information, patients with Parkinson's Disease and dystonia will be unable to use the prior (bias/memory) information to inform their decisions. Hypothesis 3: Deep Brain Stimulation (DBS) of Basal Ganglia structures will improve the ability of patients to use prior information to inform their decisions when faced with sensory uncertainty. Hypothesis 4: Both cholinergic and dopaminergic medical therapies will improve the ability of patients to use prior information to inform their decisions. Hypothesis 5: Patients with non-dystonic cerebellar damage will be similar to healthy controls in performance of a perceptual decision making task in conditions of visual uncertainty. The overarching framework of this application is that the same mechanisms (D1 striatal synaptic plasticity) that operate in reward learning play a role in learning and using stimulus priors in a perceptual decision-making task when faced with uncertainty. Because Parkinson's Disease and dystonia share deficits in striatal circuitry, the patient deficits on this task will be similar. Because non-dystonic cerebellar patients do not have dysfunction of striatal circuits, they will show no deficits in the ability to use stimulus priors to guide choices in uncertain conditions. In the event these patients do show deficits, this is will provide evidence for an unexplored role for the cerebellum in perceptual decision-making.
Detailed Description
In this study, the investigators aim determine whether patients with Parkinson's disease (PD) have altered perceptual decision-making. The results of these experiments will shed important light on some of the enigmatic symptoms seen in patients with disorders of movement. In this study the subjects perform a computer generated visual task which involves reporting the direction of an arrow that is more or less difficult to see on the computer screen. Eye movements will be monitored using a video eye tracker. The system is completely non-invasive and positioned in front, out of the subject's line of sight to avoid interfering with their ability to perform the task. Subjects will report their decision with either an eye movement in the same direction as the perception of the arrow direction. Trials will proceed as follows: a central point will appear on the screen. Subjects are asked to look at the fixation point. After this random delay time, a patch of spots will appear in place of the center fixation spot, embedded in the patch will be an arrow. The contrast between the arrow and the patch will vary from high values to low. At high contrasts the direction at which the arrow points will be very clear and at low contrasts it will be unclear. The task of the subject is to make a rapid eye movement as soon as they decide which direction the arrow points. A sound will be played to indicate a correct choice. On trials in which the sensory information is ambiguous subjects will be told to 'make their best guess' to which target the arrow points. Unknown to the subject the investigators will manipulate the probability that one of the targets is the correct one. This latter manipulation will test whether subjects can use probability information to inform their decisions. The investigators are particularly interested in whether this probability information is used preferentially when the sensory information is ambiguous. The total number of subjects to be enrolled in the study is approximately 120. Subject groups are as follows: Healthy humans between the ages of 30 and 80 and those with PD (between ages of 45 and 80), dystonia (ages 30-80) and cerebellar lesions (ages 30-80) including those who have undergone DBS surgery to treat their PD or dystonia. The total duration of each session is approximately 2 hours. Each patient group including those with DBS will perform two sessions of the same task - one while on medication and one while off medication, hence the total duration of the study will be 4 hours for these groups (2 different sessions during different days). These patient groups are free to do these sessions at the same time as their routine physician visits or any other time that works best for them.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease, Dystonia, Ataxia

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Deep Brain Stimulator
Arm Type
Other
Arm Description
Some of our subjects that participate to the study have Deep Brain Stimulation implanted. They will perform the behavioral task twice, with the stimulation ON or OFF.
Intervention Type
Procedure
Intervention Name(s)
Deep Brain Stimulation (DBS)
Intervention Description
Patients with DBS will participate to the study both when the stimulation is off and on.
Primary Outcome Measure Information:
Title
Choice performance - % correct responses out of total number of trials
Description
data from each subject will be assessed at the end of each session to monitor and measure outcome measures.
Time Frame
at the end of each testing session - 2 hours
Secondary Outcome Measure Information:
Title
Reaction Time to make a choice - measured in milliseconds
Description
data from each subject will be assessed at the end of each session to monitor and measure outcome measures.
Time Frame
at the end of each testing session - 2 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Group 1 - Age and Sex matched healthy controls: Age 18-80 Years Group 2 - Patients with Parkinson's Disease - No DBS: "on meds" and "off meds" (tested in separate sessions) - total of 2 sessions Age 45-80 Years Unified PD rating scale (UPDRS) Mini mental health Status (MMHS) Group 3 - Patients with Parkinson's Disease already consented for DBS (STN): Age 45-80 Years Unified PD rating scale (UPDRS) Mini mental health Status (MMHS) Group 4 - Patients with Parkinson's Disease already consented for DBS (GPi): Age 45-80 Years Unified PD rating scale (UPDRS) Mini mental health Status (MMHS) Group 5 - Patients with Cervical Dystonia - No DBS Age 30-80 years Fahn-Marsden dystonia rating scale (FMDRS) Mini mental health Status (MMHS) Group 6 - Patients with Generalized Dystonia (Ach) - No DBS: Age 30-80 years Fahn-Marsden dystonia rating scale (FMDRS) Mini mental health Status (MMHS) Group 7 - Patients with Dystonia already consented for DBS (GPi): Age 30-80 years Fahn-Marsden dystonia rating scale (FMDRS) Mini mental health Status (MMHS) Group 8 - Patients Cerebellar Stroke Age 30-80 Years Routine neuro exam Mini mental health Status (MMHS) Group 9 - Patients Cerebellar Ataxia Age 30-80 Years Routine neuro exam Mini mental health Status (MMHS) Exclusion Criteria: Visual impairment or ocular motility disorder Inability to sit for the 30 minute task plus 20-30 minute instruction time, setup, and wait time. For Group 1 (Age Sex Matched Controls), there will additional exclusion criteria of other neurological disease and drug use
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alessandra Perugini, PhD
Phone
3108250278
Email
APerugini@mednet.ucla.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michele Basso, PhD
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
Neuroscience Research Building
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele Basso, PhD
First Name & Middle Initial & Last Name & Degree
Alessandra Perugini, PhD

12. IPD Sharing Statement

Learn more about this trial

Perceptual Decision Making Under Conditions of Visual Uncertainty

We'll reach out to this number within 24 hrs